Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes revenue by revenue source as follows:

	Year Ended December 31,
Major Products/Service Lines (in thousands)	2024		2023		2022
Product revenue, net(1)	$	1,524,782	$	1,263,068	$	887,038
License and royalty revenues(2)	9,128		33,361		48,023
Total revenues	$	1,533,910	$	1,296,429	$	935,061

______________________________

(1)The Company’s product revenue includes PYLARIFY and DEFINITY, among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all of its principal products.

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.

Revenue by product category on a net basis is as follows:

	Year Ended December 31,
(in thousands)	2024		2023		2022
PYLARIFY	$	1,057,834	$	851,303	$	527,405
Other radiopharmaceutical oncology	384		3,130		4,102
Total radiopharmaceutical oncology	1,058,218		854,433		531,507
DEFINITY	317,792		279,768		244,993
TechneLite	95,487		87,370		88,864
Other precision diagnostics	24,231		22,980		22,825
Total precision diagnostics	437,510		390,118		356,682
Strategic Partnerships and other revenue	38,182		51,878		46,872
Total revenues	$	1,533,910	$	1,296,429	$	935,061

Schedule of Valuation and Qualifying Accounts

An analysis of the amount of, and change in, reserves is summarized as follows:

(in thousands)	Rebates and Allowances
Balance, January 1, 2023	$	13,399
Provision related to current period revenues	32,308
Adjustments relating to prior period revenues	(453)
Payments or credits made during the period	(29,184)
Balance, December 31, 2023	16,070
Provision related to current period revenues	63,504
Payments or credits made during the period	(54,326)
Balance, December 31, 2024	$	25,248

Schedule of contracts with customer

The Company recognized certain revenues as follows:

	Year Ended December 31,
(in thousands)	2024		2023
Amounts included in the contract liability at the beginning of the period	$	447	$	682